23CAS955: A randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-high recurrent platinum-sensitive epithelial ovarian, fallopi
Principal Investigator
Study Number
STUDY02001955
Summary
This study is for patients who have platinum-sensitive ovarian cancer that has come back after a first -round of treatment, who are currently on or recently have completed a second round of treatment with triplet therapy (meaning, a combination treatment with a platinum agent and bevacizumab (BEV)plus one of the following: paclitaxel or gemcitabine or pegylated lysosomal doxorubicin (PLD)), whose tumor has tested positive for high levels of folate receptor-alpha (FR ), and whose cancer has not worsened following the recent triplet therapy. The main purpose of this study is to learn more about the new drug called mirvetuximab soravtansine (MIRV) and determine if it is effective at preventing or delaying the return of platinum-sensitive ovarian cancer when administered after a triplet therapy regimen in combination with BEV.
Phase
II
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms